Development of difluoromethylornithine (DFMO) as a chemoprevention agent

Clinical Cancer Research

Volumn 5, Issue 5, 1999, Pages 945-951

  Meyskens Jr , Frank L ^a   Gerner, Eugene W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; ORNITHINE DECARBOXYLASE INHIBITOR; POLYAMINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; DOSE RESPONSE; DRUG EFFICACY; HUMAN; ONCOGENE C MYC; OTOTOXICITY; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; EFLORNITHINE; HEARING LOSS; HEMATOLOGIC DISEASES; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; ORNITHINE DECARBOXYLASE; POLYAMINES; PRECANCEROUS CONDITIONS; RODENTIA; TUMOR CELLS, CULTURED;

EID: 0345535621     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (78)

1. Cohen, S. S. A Guide to the Polyamines. New York: Oxford University Press, 1998.
2. Bachrach, U., and Weinstein, A. Effect of aliphatic polyamines on growth and macromolecular syntheses in bacteria. J. Gen. Microbiol., 60: 159-165, 1970.
3. Pohjanpelto, P., and Raina, A. Identification of a growth factor produced by human fibroblasts in vitro as putrescine. Nature New Biol., 235: 247-249, 1972.
4. Russell, D. H. The roles of the polyamines, putrescine, spermidine and spermine in normal and malignant tissues. Life Sci., 13: 1635-1647, 1973.
5. Bey, P., Danzin, C., Van Dorsselaer, V., Mamont, P., Jung, M., and Tardif, C. Analogues of ornithine as inhibitors of ornithine decarboxylase. New deductions concerning the topography of the enzyme's active site. J. Med. Chem., 21: 50-55, 1978.
6. Kolb, M., Danzin, C., Barth, J., and Claverie, N. Synthesis and biochemical properties of chemically stable product analogues of the reaction catalyzed by S-adenosyl-L-methionine decarboxylase. J. Med. Chem., 25: 550-556, 1982.
7. Bolkenius, F. N., Bey, P., and Seiler, N. Specific inhibition of polyamine oxidase in vivo is a method for the elucidation of its physiological role. Biochim. Biophys. Acta, 838: 69-76, 1985.
8. McCann, P. P., Pegg, A. E., and Sjoerdsma, A. (eds.), Inhibition of Polyamine Metabolism. Biological Significance and Basis for New Therapies. New York: Academic Press, Inc., 1987.
9. Mamont, P. S., Bohlen, P., McCann, P. P., Bey, P., Schuber, F., and Tardif, C. α-methyl ornithine, a potent competitive inhibitor of ornithine decarboxylase, blocks proliferation of rat hepatoma cells in culture. Proc. Natl. Acad. Sci. USA, 73: 1626-1630, 1976.
10. Mamont, P. S., Duchesne, M. C., Grove, J., and Bey, P. Anti-proliferative properties of D,L-α-difluoromethylornithine in cultured cells: a consequence of the irreversible inhibition of ornithine decarboxylase. Biochem. Biophys. Res. Commun., 81: 58-66, 1978.
11. Prakash, N. J., Schechter, P. J., Grove, J., and Koch-Weser, J. Effect of α-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on L1210 leukemia in mice. Cancer Res., 38: 3059-3062, 1978.
12. Danzin, C., Jung, M. J., Grove, J., and Bey, P. Effect of α-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on polyamine levels in rat tissues. Life Sci., 24: 519-524, 1979.
13. Kato, Y., Inoue, H., Gohda, E., Tamada, F., and Takeda, Y. Effect of DL-α-hydrazino-δ-aminovaleric acid, an inhibitor of ornithine decarboxylase, on polyamine metabolism and growth of mouse sarcoma-180. Gann, 67: 569-576, 1976.
14. Newton, N. E., and Abdel-Monem, M. M. Inhibitors of polyamine biosynthesis. 4. Effects of α-methyl-(+/-)-ornithine and methylglyoxal bis(guanylhydrazone) on growth and polyamine content of L1210 leukemic cells of mice. J. Med. Chem., 20: 249-253, 1977.
15. Steglich, C., and Scheffler, I. E. An ornithine decarboxylase-deficient mutant of Chinese hamster ovary cells. J. Biol. Chem., 257: 4603-4609, 1982.
16. Pohjanpelto, P., Holtta, E., and Janne, O. A. Mutant strain of Chinese hamster ovary cells with no detectable ornithine decarboxylase activity. Mol. Cell. Biol., 5: 1385-1390, 1985.
17. Tabor, H., Tabor, C. W., Cohn, M. S., and Hafner, E. W. Streptomycin resistance (rpsL) produces an absolute requirement for polyamines for growth of an Escherichia coli strain unable to synthesize putrescine and spermidine [Δ(speA-speB) Δ specC]. J. Bacteriol., 147: 702-704, 1981.
18. Tabor, C. W., Tabor, H., Tyagi, A. K., and Cohn, M. S. The biochemistry, genetics, and regulation of polyamine biosynthesis in Saccharomyces cerevisiae. Fed. Proc., 41: 3084-3088, 1982.
19. Balasundaram, D., Tabor, C. W., and Tabor, H. Spermidine or spermine is essential for the aerobic growth of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA, 88: 5872-5876, 1991.
20. Xie, Q. W., Tabor, C. W., and Tabor, H. Deletion mutations in the speED operon: spermidine is not essential for the growth of Escherichia coli. Gene (Amst.), 126: 115-117, 1993.
21. Bacchi, C. J., Nathan, H. C., Hutner, S. H., McCann, P. P., and Sjoerdsma, A. Polyamine metabolism: a potential therapeutic target in trypanosomes. Science (Washington DC), 210: 332-334, 1980.
22. Fairlamb, A. H., Henderson, G. B., Bacchi, C. J., and Cerami, A. In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. Mol. Biochem. Parasitol., 24: 185-191, 1987.
23. Fuller, D. J., and Gerner, E. W. Delayed sensitization to heat by inhibitors of polyamine-biosynthetic enzymes. Cancer Res., 42: 5046-5049, 1982.
24. Oredsson, S. M., Deen, D. F., and Marton, L. J. Decreased cytotoxicity of cis-diamminedichloroplatinum(II) by α-difluoromethylornithine depletion of polyamines in 9L rat brain tumor cells in vitro. Cancer Res., 42: 1296-1299, 1982.
25. Claverie, N., and Mamont, P. S. Comparative antitumor properties in rodents of irreversible inhibitors of L-ornithine decarboxylase, used as such or as prodrugs. Cancer Res., 49: 4466-4471, 1989.
26. Barranco, S. C., Ford, P. J., and Townsend, C. M., Jr. Heterogeneous survival and cell kinetics responses of human astrocytoma clones to α-difluoromethylornithine in vitro. Invest. New Drugs, 7: 155-161, 1989.
27. Peralta Soler, A., Gilliard, G., Megosh, L., George. K., and O'Brien, T. G. Polyamines regulate expression of the neoplastic phenotype in mouse skin. Cancer Res., 58: 1654-1659, 1998.
28. Packham, G., Porter, C. W., and Cleveland J. L. c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Oncogene, 13: 461-469, 1996.
29. Megosh, L., Halpern, M., Farkash, E., and O'Brien, T. G. Analysis of ras gene mutational spectra in epidermal papillomas from K6/ODC transgenic mice. Mol. Carcinog., 22: 145-149, 1998.
30. Packham, G., and Cleveland, J. L. The role of ornithine decarboxylase in c-Myc-induced apoptosis. Curr. Top. Microbiol. Immunol., 194: 283-290, 1995.
31. Tome, M. E., Fiser, S. M., Payne, C. M., and Gerner, E. W. Excess putrescine accumulation inhibits the formation of modified eukaryotic initiation factor 5A(eIF-5A) and induces apoptosis. Biochem. J., 328: 847-854, 1997.
32. Verma, A. K. Inhibition of tumor promotion by DL-α-difluoromethylornithine, specific irreversible inhibitor of ornithine decarboxylase. Basic Life Sci., 52: 195-204, 1990.
33. Hixson, L. J., Garewal, H. S., McGee, D., Sloan, D., Fennerty, M. B., Sampliner, R. E., and Gerner, E. W. Ornithine decarboxylase and polyamines in colorectal neoplasia and adjacent mucosa. Cancer Epidemiol. Biomark. Prev., 2: 369-374, 1993.
34. Rozhin, J., Wilson, P. S., Bull, A. W., and Nigro, N. D. Ornithine decarboxylase activity in the rat and human colon. Cancer Res., 44: 3226-3230, 1984.
35. Tempero, M. Bile acids, ornithine decarboxylase, and cell proliferation in colon cancer: a review. Dig. Dis., 4: 49-56, 1986.
36. Augenlicht, L. H., Wadler, S., Corner, G., Richards, C., Ryan, L., Multani, A. S., Pathak, S., Benson, A., Haller, D., and Heerdt, B. G. Low-level c-myc amplification in human colonie carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res., 57: 1769-1775, 1997.
37. Bello-Fernandez, C., Packham, G., and Cleveland, J. L. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc. Natl. Acad. Sci. USA, 90: 7804-7808, 1993.
38. Pena, A., Reddy, C. D., Wu, S., Hickok, N. J., Reddy, E. P., Yumet, G., Soprano, D. R., and Soprano, K. J. Regulation of human ornithine decarboxylase expression by the c-Myc.Max protein complex. J. Biol. Chem., 268: 27277-27285, 1993.
39. Su, L. K., Kinzler, K. W., Vogelstein, B., Preisinger, A. C., Moser, A. R., Luongo, C., Gould, K. A., and Dove W. F. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science (Washington DC), 256: 668-670, 1992.
40. He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., and Kinzler, K. W. Identification of c-MYC as a target of the APC pathway. Science (Washington DC), 281: 1509-1512, 1998.
41. Gerner, E. W., and Mamont, P. S. Restoration of polyamine contents in rat hepatoma (HTC) cells after inhibition of polyamine biosynthesis: relationship with cell proliferation. Eur. J. Biochem., 156: 31-35, 1986.
42. Meyskens, F. L., Jr., Gerner, E., Emerson, S., Pelot, D., Durbin, T., Doyle, K., and Lagerberg, W. A randomized double-blind placebo controlled Phase IIb trial of difluoromethylornithine for colon cancer prevention. J. Natl. Cancer Inst., 90: 1212-1218, 1998.
43. Nigro, N. D., Bull, A. W., and Boyd, M. E. Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J. Natl. Cancer Inst., 77: 1309-1313, 1986.
44. Thompson, H. J., and Ronan, A. M. Effect of D,L-2-difluoromethylornithine and endocrine manipulation on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis (Lond.), 7: 2003-2006, 1986.
45. Nowels, K., Homma, Y., Seidenfeld, J., and Oyasu R. Prevention of inhibitory effects of α-difluoromethylornithine on rat urinary bladder carcinogenesis by exogenous putrescine. Cancer Biochem. Biophys., 8: 257-263, 1986.
46. Halline, A. G., Dudeja, P. K., Jacoby, R. F., Llor, X., Teng, B. B., Chowdhury, L. N., Davidson, N. O., and Brasitus, T. A. Effect of polyamine oxidase inhibition on the colonic malignant transformation process induced by 1,2-dimethylhydrazine. Carcinogenesis (Lond.), 11: 2127-2132, 1990.
47. Slaga, T. J. Multistage skin carcinogenesis: a useful model for the study of the chemoprevention of cancer. Acta Pharmacol. Toxicol., 55 (Suppl. 2): 107-124, 1984.
48. Wallon, U. M., Shassetz, L. R., Cress, A. E., Bowden, G. T., and Gerner, E. W. Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer cell line. Mol. Carcinog., 11: 138-144, 1994.
49. Kubota, S., Kiyosawa, H., Nomura, Y., Yamada, T., and Seyama, Y. Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. J. Natl Cancer Inst., 89: 567-571, 1997.
50. Smith, M. K., Goral, M. A., Wright, J. H., Matrisian, L. M., Morris, R. J., Klein-Szanto, A. J., and Gilmour, S. K. Ornithine decarboxylase overexpression leads to increased epithelial tumor invasiveness. Cancer Res., 57: 2104-2108, 1997.
51. Hixson, L. J., Emerson, S. S., Shassetz, L. R., and Gerner, E. W. Sources of variability in measurements of ornithine decarboxylase activity and polyamine contents in colorectal mucosa. Cancer Epidemiol Biomark. Prev., 3: 317-323, 1994.
52. Dunzendorfer, U., and Knoner, M. Therapy with inhibitors of polyamine biosynthesis in refractory prostatic carcinoma: an experimental and clinical study. Onkologie, 8: 196-200, 1985.
53. Abeloff, M. D., Slavik, M., Luk, G. D., Griffin, C. A., Hermann, J., Blanc, O., Sjoerdsma, A., and Baylin, S. B. Phase I trial, and pharmacokinetic studies of α-difluoromethylornithine - an inhibitor of polyamine biosynthesis. J. Clin. Oncol., 2: 124-130, 1984.
54. Abeloff, M. D., Rosen, S. T., Luk, G. D., Baylin, S. B., Zeltzman, M., and Sjoerdsma, A. Phase II trials of α-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer. Cancer Treat. Rep., 70: 843-845, 1986.
55. Meyskens, F. L., Kingsley, E. M., Glattke, T., Loescher, L., and Booth, A. A Phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma. Invest. New Drugs, 4: 257-262, 1986.
56. Talpaz, M., Plager, C., Quesada, J., Benjamin, R., Kantajian, H., and Gutterman, J. Difluoromethylornithine and leukocyte Interferon: a Phase I in cancer patients. Eur. J. Cancer & Clin. Oncol., 22: 685-689, 1986.
57. Harari, P. M., Fuller, D. J. M., Carper, S. W., Croghan, M. K., Meyskens, F. L., Jr., Shimm, D. S., and Gerner, E. W. Polyamine biosynthesis inhibitors combined with systemic hyperthermia in cancer therapy. Int. J. Radiat. Oncol. Biol. Phys., 19: 89-96, 1990.
58. Schweitzer, V. G. Ototoxicity of chemotherapeutic agents. Otolaryngol. Clin. N. Am., 26: 759-789, 1993.
59. Prados, M., Rodriguez, L., Chamberlain, M., Silver, P., and Levin, V. Treatment of recurrent gliomas with 1,3-bix(2-chloroethyl-1-nitrosourea and α-difluoromethylornithine. Neurosurgery (Baltimore), 24: 806-809, 1989.
60. Love, R. R., Carbone, P. P., Verma, A. K., Gilmore, D., Carey, P., Tutsch, K. D., Pomplun, M., and Wilding, G. Randomized Phase I chemoprevention dose-seeking study of α-difluoromethylornithine. J. Natl. Cancer Inst., 85: 732-736, 1993.
61. Carbone, P. P., Douglas, J. A., Larson, P. O., Verma, A. K., Blair, I. A., and Tutsch, K. Phase I chemoprevention study of piroxicam (PXM), and α-difluoromethylornithine (DFMO). Cancer Epidemiol. Biomark. Prev., 7: 907-912, 1998.
62. Nishioka, K., Melgarejo, A. B., Lyon, R. R., and Mitchell, M. F. Polyamines as biomarkers of cervical intraepithelial neoplasia. J. Cell. Biochem., 23 ( Suppl.): 87-95, 1995.
63. Mitchell, M. F., Hittelman, W. K., Lotan, R., Nishioka, K., Tortolero-Luna, G., Richards-Kortum, R. R., Wharton, J. T., and Hong, W. K. Chemoprevention trials and surrogate end point biomarkers in the cervix. Cancer (Phila.), 76 (Suppl): 1956-1977, 1995.
64. Mitchell, M. F., Tortolero-Luna, G., Lee, J. J., Hittelman, W. N., Lotan, R., Wharton J. T., Hong, W. K., and Nishioka, K. Phase I dose de-escalation trial of α-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin. Cancer Res., 4: 303-310, 1998.
65. Boyle, J. O., Meyskens, F. L., Jr., Garewal, H. S., and Gerner, E. W. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine. Cancer Epidemiol. Biomark. Prev., 1: 131-135, 1992.
66. Meyskens, F. L., Jr., Emerson, S. S., Pelot, D., Meshkinpour, H., Shassetz, R., Einspahr, J., Alberts, D. S., and Gerner, E. W. Dose de-escalation chemoprevention trial of α-difluoromethylornithine in patients with colon polyps. J. Natl. Cancer Inst., 86: 1122-1130, 1994.
67. Love., R. R., Jacoby, R., Newton, M. A., Tutsch, K. D., Simon, K., Pomplun, M., and Verma, A. K. A randomized, placebo-controlled trial of low dose α-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiol. Biomark. Prev., 7: 989-992, 1998.
68. Wang, W., Liu, L. Q., and Higuchi, C. M. Mucosal polyamine measurements and colorectal cancer risk. J. Cell. Biochem., 63: 252-257, 1996.
69. Meyskens, F. L., Jr., Surwit, E., Moon, T. E., Childers, J. M., Davis, J. R., Dorr, R., Johnson, C. S., and Alberts, D. S. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J. Natl. Cancer Inst., 86: 539-543, 1994.
70. Butterworth, C. E., Jr., Hatch, K. D., Macaluso, M., Cole, P., Sauberlich, H. E., Soong, S. J., Borst, M., and Baker, V. V. Folate deficiency and cervical dysplasia. J. Am. Med. Assoc., 267: 528-533, 1992.
71. Childers, J. M., Chu, J., Voigt, L. F., Tamimi, H. K., Franklin, E. W., Alberts, D. S., and Meyskens, F. L., Jr. Chemoprevention of cervical cancer with folic acid: a Phase III Southwest Oncology Group Intergroup study. Cancer Epidemiol. Biomark. Prev., 4: 155-159, 1995.
72. Romney, S. L., Ho, G. Y., Palan, P. R., Basu, J., Kadish, A. S., Klein, S., Mikhail, M., Hagan, R. J., Chang, C. J., and Burk, R. D. Effects of β-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol. Oncol., 65: 483-492, 1997.
73. Keefe, K. A., Wilczynski, S., Lagerberg, W., Brewer, C., Chapman, J., Upsani, S., and Berman, M. Effects of β-carotene on cervical intrepithelial neoplasia (CIN): a Phase II trial. Twenty-ninth Annual Society of Gynecologic Oncologists Meeting. Gynecol. Oncol., 68: 110, 1998.
74. Croghan, M. K., Aicken, M. G., and Meyskens, F. L., Jr. Dose-related α-difluoromethylornithine (DFMO) ototoxicity (reversible hearing loss). Am. J. Clin. One., 14: 331-335, 1991.
75. Pasic, T. R., Heisey, D., and Love, R. R. α-Difluoromethylornithine ototoxicity: chemoprevention clinical trial results. Arch. Otolaryngol. Head Neck Surg., 123: 1281-1286, 1997.
76. Loprinzi, C. L., Messing, E. M., O'Fallon J. R., Poon, M. A., Love, R. R., Quella, S., K., Trump, D. L., Morton, R. F., and Novotny, P. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Cancer Epidemiol. Biomark. Prev., 5: 371-374, 1996.
77. Morrell, C. H., Gordon-Salant, S., Pearson, J. D., Brant, L. J., and Fozard, J. L. Age-and gender-specific reference ranges for hearing level and longitudinal changes in hearing level. J. Acoust. Soc. Am., 100: 1949-1967, 1996.
78. Wiley, T. L., Cruickshanks, K. J., Nondahl, D. M., Tweed, T. S., Klein R., and Klein, B. E. K. Aging, and high-frequency hearing sensitivity. J. Speech Lang. Hear. Res., 41: 1061-1072, 1998.